公开(公告)号：US20240189439A1

公开(公告)日：2024-06-13

申请号：US18454457

申请日：2023-08-23

Applicant: Novartis AG

Inventor： Matthew Burger ,  Joseph Anthony D'Alessio ,  Tony Fleming ,  Vivek Rauniyar ,  Eusebio Manchado Robles ,  Christian Kunz ,  Markus Waldhuber

IPC: A61K47/68 ,  A61K31/4745 ,  A61P35/00 ,  C07K16/18

CPC classification number: A61K47/6803 ,  A61K31/4745 ,  A61P35/00 ,  C07K16/18 ,  A61K45/06

Abstract: This application discloses anti-PMEL17 antibodies, antigen binding fragments thereof, and antibody drug conjugates of said antibodies or antigen binding fragments conjugated to a GNAQ/GNA11 inhibitor. The invention also relates to methods of treating or preventing cancer using the antibodies, antigen binding fragments, and antibody drug conjugates. Also disclosed herein are methods of making the antibodies, antigen binding fragments, and antibody drug conjugates, and methods of using the antibodies and antigen binding fragments as diagnostic reagents.

公开(公告)号：US11779649B2

公开(公告)日：2023-10-10

申请号：US16718866

申请日：2019-12-18

Applicant: Novartis AG

Inventor： Matthew Burger ,  Joseph Anthony D'Alessio ,  Tony Fleming ,  Vivek Rauniyar ,  Eusebio Manchado Robles ,  Christian Kunz ,  Markus Waldhuber

IPC: A61K47/68 ,  A61P35/00 ,  A61K31/4745 ,  C07K16/18 ,  A61K45/06

CPC classification number: A61K47/6803 ,  A61K31/4745 ,  A61P35/00 ,  C07K16/18 ,  A61K45/06

Abstract: This application discloses anti-PMEL17 antibodies, antigen binding fragments thereof, and antibody drug conjugates comprising antibodies or antigen binding fragments conjugated to a GNAQ/GNA11 inhibitor. The application also discloses methods of treating or preventing cancer using the antibodies, antigen binding fragments, and antibody drug conjugates. Also disclosed herein are methods of making the antibodies, antigen binding fragments, and antibody drug conjugates, and methods of using the antibodies and antigen binding fragments as diagnostic reagents.

公开(公告)号：US20240299574A1

公开(公告)日：2024-09-12

申请号：US18672871

申请日：2024-05-23

Applicant: Novartis AG

Inventor： Matthew Burger ,  Joseph A. D'Alessio ,  Tony Fleming ,  Vivek Rauniyar ,  Eusebio Manchado Robles

IPC: A61K47/68 ,  A61K31/4745 ,  A61K45/06 ,  A61P35/00 ,  C07K16/18

CPC classification number: A61K47/6803 ,  A61K31/4745 ,  A61P35/00 ,  C07K16/18 ,  A61K45/06

Abstract: This application discloses anti-PMEL17 antibodies, antigen binding fragments thereof, and antibody drug conjugates of said antibodies or antigen binding fragments conjugated to a GNAQ/GNA11 inhibitor. The invention also relates to methods of treating or preventing cancer using the antibodies, antigen binding fragments, and antibody drug conjugates. Also disclosed herein are methods of making the antibodies, antigen binding fragments, and antibody drug conjugates, and methods of using the antibodies and antigen binding fragments as diagnostic reagents.

公开(公告)号：US20240252668A1

公开(公告)日：2024-08-01

申请号：US18286664

申请日：2022-04-15

Applicant: Anne-Sophie BLUEMMEL ,  Kathrin BUNTIN ,  Joseph Anthony D'ALESSIO ,  Liqiong FAN ,  Boris FESSLER ,  Doris GABRIEL ,  Dominik HAINZL ,  Keith HOFFMASTER ,  Shwetha IYER ,  Eshita KHERA ,  Eusebio Manchado ROBLES ,  Pierre MAUDENS ,  Dominik PISTORIUS ,  Roee RAMOT ,  Vincent ROMANET ,  Kuno WUERSCH ,  Padmaja YERRAMILLI-RAO ,  Novartis AG

Inventor： Liqiong Fan ,  Dominik Hainzl ,  Roee Ramot ,  Shwetha Iyer ,  Joseph Anthony D'Alessio ,  Kuno Wuersch ,  Dominik Pistorius ,  Eusebio Manchado Robles ,  Kathrin Buntin ,  Doris Gabriel ,  Boris Fessler ,  Pierre Maudens ,  Vincent Romanet ,  Anne-Sophie Bluemmel ,  Keith Hoffmaster ,  Eshita Khera ,  Padmaja Yerramilli-Rao

IPC: A61K47/68 ,  A61P35/00 ,  C07K11/02 ,  C07K14/47 ,  C07K16/28 ,  C12N9/00 ,  C12N9/02 ,  C12N9/04 ,  C12N9/18 ,  C12N15/52 ,  C12P21/02 ,  C12R1/01 ,  G01N33/574

CPC classification number: A61K47/6849 ,  A61K47/6811 ,  A61K47/6865 ,  A61P35/00 ,  C07K11/02 ,  C07K14/4722 ,  C07K16/28 ,  C12N9/0006 ,  C12N9/0073 ,  C12N9/18 ,  C12N9/93 ,  C12N15/52 ,  C12P21/02 ,  C12Y301/01001 ,  G01N33/57492 ,  C12R2001/01

Abstract: This application discloses microorganisms and methods of producing GNAQ/GNA11 inhibitors and methods of making antibody drug conjugates of anti-PMEL17 antibodies or antigen binding fragments conjugated to a GNAQ/GNA11 inhibitor. The disclosure also relates to formulations comprising antibody drug conjugates of anti-PMEL 17 antibodies or antigen binding fragments conjugated to a GNAQ/GNA1 inhibitor and methods of treating or preventing cancer using the formulations.